Literature DB >> 6754251

Ultrastructure of uteroplacental arteries.

F De Wolf, I Brosens, W B Robertson.   

Abstract

Ultrastructural study of the placental bed spiral arteries confirms that non-villous cytotrophoblast is involved in the development of the physiological changes occurring in these vessels during normal pregnancy. The changes observed in the myometrial segments of the spiral arteries before the time of arrival of endovascular trophoblast but after the invasion of the myometrium by migrating interstitial trophoblast, are characterised by widening of the lumen, oedema of the intima, disruption of the elastica and widening of the intercellular spaces of the media. This vascular distension could facilitate the subsequent retrograde migration of endovascular trophoblast. The fetal cells migrate in the vessel lumen and infiltrate the subendothelial space causing further disruption of the arterial intima and media. The altered intima is subsequently recovered by the endothelium. In this way, the cytotrophoblast is incorporated into the wall of the placental bed spiral arteries which are converted from small muscular arteries into distended hyalinized tubes. In pregnancies complicated by preeclampsia and in some pregnancies complicated by fetal growth retardation, these physiological changes are largely restricted to the decidual segments leaving the myometrial segments unaffected. The lesion of acute atherosis is characterised by thickening of the intima and necrosis of the media. The intimal thickening is due to deposition of fibrin and other plasma constituents and migration into the intima of macrophages and myointimal cells which accumulate fat in their cytoplasm to become foam cells. Clinical and experimental studies indicate that these lesions can be initiated by several factors which cause endothelial injury.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6754251

Source DB:  PubMed          Journal:  Contrib Gynecol Obstet        ISSN: 0304-4246


  7 in total

1.  The effects of kisspeptin-54 on blood pressure in humans and plasma kisspeptin concentrations in hypertensive diseases of pregnancy.

Authors:  Gurjinder M K Nijher; Owais B Chaudhri; Radha Ramachandran; Kevin G Murphy; Sagen E K Zac-Varghese; Alexis Fowler; Krishna Chinthapalli; Michael Patterson; Emily L Thompson; Catherine Williamson; Sailesh Kumar; Mohammad A Ghatei; Stephen R Bloom; Waljit S Dhillo
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

Review 2.  Establishment of the Human Uteroplacental Circulation: A Historical Perspective.

Authors:  Kenna Degner; Ronald R Magness; Dinesh M Shah
Journal:  Reprod Sci       Date:  2016-10-12       Impact factor: 3.060

Review 3.  Beyond the threshold: an etiological bridge between hypoxia and immunity in preeclampsia.

Authors:  Surendra Sharma; Wendy E Norris; Satyan Kalkunte
Journal:  J Reprod Immunol       Date:  2010-03-16       Impact factor: 4.054

Review 4.  The role of RAS in the pathogenesis of preeclampsia.

Authors:  Dinesh M Shah
Journal:  Curr Hypertens Rep       Date:  2006-05       Impact factor: 5.369

5.  Role of sex steroids in modulating tumor necrosis factor alpha-induced changes in vascular function and blood pressure.

Authors:  Babbette D LaMarca; Derrick L Chandler; Lee Grubbs; Jennifer Bain; Gerald R McLemore; Joey P Granger; Michael J Ryan
Journal:  Am J Hypertens       Date:  2007-11       Impact factor: 2.689

Review 6.  Acute Atherosis Lesions at the Fetal-Maternal Border: Current Knowledge and Implications for Maternal Cardiovascular Health.

Authors:  Daniel Pitz Jacobsen; Heidi Elisabeth Fjeldstad; Guro Mørk Johnsen; Ingrid Knutsdotter Fosheim; Kjartan Moe; Patji Alnæs-Katjavivi; Ralf Dechend; Meryam Sugulle; Anne Cathrine Staff
Journal:  Front Immunol       Date:  2021-12-14       Impact factor: 7.561

Review 7.  Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders.

Authors:  Sarosh Rana; Suzanne D Burke; S Ananth Karumanchi
Journal:  Am J Obstet Gynecol       Date:  2020-10-20       Impact factor: 8.661

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.